Dylan Dupuis, Ph.D., has joined ROTH MKM’s healthcare research team as managing director, senior research analyst covering biotechnology. His research coverage is expected to include micro-cap and small-cap...
Heron Therapeutics (NASDAQ:HRTX) appointed three new directors to the board, including Kevin Kotler, a renowned healthcare investor, founder and portfolio manager of Broadfin Capital. Mr. Kotler has over 30 years of...
Elucid, a closely-held medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, appointed Scott Burger as chief commercial officer. His...
Raymond James Ltd. (CNW Group/Raymond James Ltd.) Raymond James again expanded its healthcare investment banking practice with the addition of three senior bankers. Joining the firm as managing directors are Jeff...
Soricimed Biopharma appointed Dr. Siqing Fu, a North American leader in cancer research, to its scientific advisory board. Dr. Fu has more than 20 years of experience in cancer research and is currently a professor in...
Closely-held Ripple Therapeutics appointed Jonathan Talamo, M.D., currently a member of the board, to be chairman. Dr. Talamo is internationally known as an experienced surgeon and thought leader in ophthalmology, with...
Palisade Bio (NASDAQ:PALI) named JD Finley, CFO, as interim CEO, replacing Thomas Hallam, Ph.D., effective Oct. 10. In a statement, James Neal, chairman of Palisade, said Dr. Hallam was “instrumental in the development...
Kumaraguru Raja, Ph.D., joined ROTH Capital Partners healthcare research team, as managing director, senior research analyst covering biotechnology. His research coverage is expected to include micro-cap and small-cap...
Sigyn Therapeutics (OTCQB:SIGY) appointed Richa Nand, Jim Dorst, and Christopher Wetzel to its board, effective Oct. 10, 2022. “As we transition toward the next phase of our clinical endeavors, it is an opportune...
Paul Brennan Paul Brennan is stepping down as president, CEO and a director of NervGen Pharma (OTCQX:NGENF; TSXV:NGEN), effective immediately. The board appointed current executive chairman, Bill Radvak, as interim CEO...